Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer Vfend Sets New Efficacy Standard In Invasive Aspergillosis, FDA Says

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Vfend’s marked efficacy in invasive aspergillosis makes the Pfizer antifungal attractive as an active comparator in studies for the indication, FDA review documents suggest.

You may also be interested in...

Fuzeon Discontinuations From Injection Reactions Remain Low At 48 Weeks

Roche/Trimeris’ 48-week follow-up data for Fuzeon show a continued low rate of discontinuation due to injection site reactions.

Pfizer Vfend Cardiac Safety Studies Needed For Esophageal Candida Approval

Approval of Pfizer’s Vfend for treatment of esophageal candidiasis depends on completion of cardiac studies to rule out an unacceptable risk of QTc prolongation, review documents for the triazole antifungal indicate.

Fujisawa Micafungin Safety, Prophylatic Use Could Be Benefits Vs. Cancidas

Fujisawa is looking to differentiate its I.V. echinocandin antifungal agent, micafungin, from Merck’s Cancidas by indications and safety profile.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts